TScan Therapeutics Inc. (NASDAQ:TCRX) shares traded -3.85% lower at $2.00 on Wall Street last session.
In accordance with the data, 5 analysts cover TScan Therapeutics Inc. (NASDAQ:TCRX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $21.00 and a low of $6.00, we find $14.50. Given the previous closing price of $2.08, this indicates a potential upside of 597.12 percent. TCRX stock price is now -2.67% away from the 50-day moving average and -27.58% away from the 200-day moving average. The market capitalization of the company currently stands at $47.72M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 0 analysts and a buy by 4. Brokers who have rated the stock have averaged $14.00 as their price target over the next twelve months.
.
In other news, Silver Brian M., Chief Financial Officer bought 3,158 shares of the company’s stock on Dec 28. The stock was bought for $4,941 at an average price of $1.56. Upon completion of the transaction, the Chief Financial Officer now directly owns 32,885 shares in the company, valued at $65770.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 27, Chief Financial Officer Silver Brian M. bought 2,842 shares of the business’s stock. A total of $4,276 was incurred on buying the stock at an average price of $1.50. This leaves the insider owning 29,727 shares of the company worth $59454.0. A total of 7.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TCRX stock. A new stake in TScan Therapeutics Inc. shares was purchased by PRIVIUM FUND MANAGEMENT (UK) LTD during the first quarter worth $32,000. PRUDENTIAL FINANCIAL INC invested $22,000 in shares of TCRX during the first quarter. In total, there are 33 active investors with 63.50% ownership of the company’s stock.
TScan Therapeutics Inc. (NASDAQ: TCRX) opened at $1.9000 on Tuesday. During the past 12 months, TScan Therapeutics Inc. has had a low of $1.45 and a high of $5.60. As of last week, the company has a debt-to-equity ratio of 0.25, a current ratio of 8.50, and a quick ratio of 8.50. The fifty day moving average price for TCRX is $2.0548 and a two-hundred day moving average price translates $2.7616 for the stock.
The latest earnings results from TScan Therapeutics Inc. (NASDAQ: TCRX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.63, beating analysts’ expectations of -$0.75 by 0.12. This compares to -$0.80 EPS in the same period last year. The company reported revenue of $3.36 million for the quarter, compared to $2.41 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 39.43 percent. For the current quarter, analysts expect TCRX to generate $3.7M in revenue.
TScan Therapeutics Inc.(TCRX) Company Profile
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
